Inhalable nanomedicine for lung cancer treatment

被引：0
作者：
Zhang S. [1 ]
Li R. [1 ]
Jiang T. [1 ]
Gao Y. [1 ]
Zhong K. [1 ]
Cheng H. [1 ,3 ]
Chen X. [1 ]
Li S. [1 ,2 ]
机构：
[1] Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou
[2] Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou
[3] Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou
来源：
Smart Materials in Medicine | 2024年 / 5卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Inhalation; Lung cancer; Nanomedicine; Targeted treatment;
D O I：
10.1016/j.smaim.2024.04.001
中图分类号：
学科分类号：
摘要：
Lung cancer has surpassed other types of cancer to become the primary cause of cancer-related deaths. Surgery stands as the foremost clinical treatment strategy available for tackling this condition, but it receives a low efficiency for most patients. In recent years, some adjuvant therapies are employed to improve the lung cancer treatment efficiency, such as chemotherapy, targeted therapy and immunotherapy. However, these strategies have not significantly increased overall survival of patients. Additionally, the random distribution of drugs will induce severe side effects. Nanomedicines have got great attentions to boost drug effect and reduce adverse reactions, including liposome-based nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and exosomes. Importantly, nanomedicines contribute to improving drug bioavailability, stability and residency in target regions. Benefiting from the physiological characteristics of lung, the inhaled pulmonary delivery strategy in combination with nanomedicine will provide a non-invasive and effective strategy for treating lung cancer. Furthermore, the use of targeting ligands enables precise delivery of loaded drugs to lung cancer cells. Inhaled nanomedicine exhibits unique distribution and sustained release behaviors in the alveoli, amplifying the therapeutic effect and reducing side effects. This review aims to discuss various inhaled methods of delivering nanomedicine to treat lung cancer and also summarizes the clearance mechanism of nanomedicine in the lung. Overall, this review focuses on the application of different inhalable nanomedicines, which may inspire the development of more effective treatments against lung cancer. © 2024 The Authors
引用
收藏
页码：261 / 280
页数：19
相关论文
共 154 条
[41]  
Rosiere R., Gelbcke M., Mathieu V., Van Antwerpen P., Amighi K., Wauthoz N., New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy, Int. J. Oncol., 47, 3, pp. 1131-1142, (2015)
[42]  
Willis L., Hayes D., Mansour H.M., Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery, Lung, 190, 3, pp. 251-262, (2012)
[43]  
Alves G.P., Santana M.H.A., Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties, Powder Technol., 145, 2, pp. 139-148, (2004)
[44]  
Muralidharan P., Malapit M., Mallory E., Hayes D., Mansour H.M., Inhalable nanoparticulate powders for respiratory delivery, Nanomed. Nanotechnol. Biol. Med., 11, 5, pp. 1189-1199, (2015)
[45]  
Douafer H., Andrieu V., Brunel J.M., Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases, J. Contr. Release, 325, pp. 276-292, (2020)
[46]  
Mishra B., Singh J., Novel drug delivery systems and significance in respiratory diseases, Target. Chronic Inflamm, Lung Dis. Using Adv. Drug Deliv. Syst, pp. 57-95, (2020)
[47]  
Abdelaziz H.M., Teleb M., Khattab S.N., Bekhit A.A., Elkhodairy K.A., Elzoghby A.O., Recent Advances in Inhalable Nanomedicine for Lung Cancer Therapy, Organ Specif. Drug Deliv. Target, pp. 239-270, (2022)
[48]  
Respaud R., Vecellio L., Diot P., Heuze-Vourc'h N., Nebulization as a delivery method for mAbs in respiratory diseases, Expet Opin. Drug Deliv., 12, 6, pp. 1027-1039, (2015)
[49]  
Abdelaziz H.M., Gaber M., Abd-Elwakil M.M., Mabrouk M.T., Elgohary M.M., Kamel N.M., Kabary D.M., Freag M.S., Samaha M.W., Mortada S.M., Elkhodairy K.A., Fang J.-Y., Elzoghby A.O., Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates, J. Contr. Release, 269, pp. 374-392, (2018)
[50]  
Rosiere R., Amighi K., Wauthoz N., Nanomedicine-based inhalation treatments for lung cancer, Nanotechnol. Based Target, Drug Deliv. Syst. Lung Cancer, pp. 249-268, (2019)
12345678910